The Bioinformatics Core was created to provide and build bioinformatics services and infrastructure for the MSKCC research community. The services of the core include scientific consultations, high performance computing and high capacity data storage support, training via clinics and workshops, custom programming on both small and large scale software projects, and pipelines for data analysis. The Core has grown to 13 full time staff members including PhD level research scientists and a professional staff of engineers, programmers and systems administrators. The Core provides all levels of bioinformatics support from small scale script writing to long term analytic support. As new technologies emerge, such as next-generation sequencing, the Core's focus and services have grown to meet them. The broad range of services and collaborative work provided by the Bioinformatics Core has supported the research of 66 investigators in the past year. During the past grant period the work of the Core has contributed to 365 publications of researchers from 8 research programs. For example, the Core supported Drs. Sawyers, Gerald, and Sander in the analysis of genomic datasets generated by the MSKCC Genomics Core from 214 primary and metastatic prostate cancer samples that were obtained from the MSKCC Pathology Core. The Core developed the informatics pipeline for analysis of exon resequencing data, generated plots of copy number alterations from array CGH data, and conducted preliminary analyses of the mRNA transcriptome and microRNA expression data from arrays run by the Genomics Core. This work led to the first comprehensive integrated genomic analysis of prostate cancer and has served as a key source of information for the field since its publication in 2010.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-51
Application #
9204776
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-01-01
Budget End
2017-12-31
Support Year
51
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Hu, Zishuo I; Shia, Jinru; Stadler, Zsofia K et al. (2018) Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin Cancer Res 24:1326-1336
Connors, Joseph M; Jurczak, Wojciech; Straus, David J et al. (2018) Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med 378:331-344
Reznik, Ed; Luna, Augustin; Aksoy, Bülent Arman et al. (2018) A Landscape of Metabolic Variation across Tumor Types. Cell Syst 6:301-313.e3
Barbetta, Arianna; Hsu, Meier; Tan, Kay See et al. (2018) Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 155:2710-2721.e3
Feldman, Darren R; Ardeshir-Rouhani-Fard, Shirin; Monahan, Patrick et al. (2018) Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. Clin Genitourin Cancer 16:e761-e769
Shumway, Dean A; McLeod, Chandler M; Morrow, Monica et al. (2018) Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. Int J Radiat Oncol Biol Phys 100:1237-1245
García Nores, Gabriela D; Ly, Catherine L; Cuzzone, Daniel A et al. (2018) CD4+ T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema. Nat Commun 9:1970
Morris, Patrick G; Rota, Selene; Cadoo, Karen et al. (2018) Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clin Breast Cancer 18:387-394
McMurry, Timothy L; Stukenborg, George J; Kessler, Larry G et al. (2018) More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival: A Nationally Representative Cohort Study. Ann Surg 268:632-639
Floros, Konstantinos V; Lochmann, Timothy L; Hu, Bin et al. (2018) Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. Proc Natl Acad Sci U S A 115:E2594-E2603

Showing the most recent 10 out of 8799 publications